ACP
DNTH icon

Acuta Capital Partners’s Dianthus Therapeutics DNTH Stock Holding History

Acuta Capital Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,708
Closed -$689K – 29
2025
Q4 		$689K Sell
16,708
-8,292
-33% -$321K 0.47% 25
2025
Q3 		$984K Buy
+25,000
New +$639K 1.02% 21
2018
Q4 		– Sell
-10,625
Closed -$2.04M – 28
2018
Q3 		$2.04M Hold
10,625
– – 0.73% 23
2018
Q2 		$2.29M Buy
+10,625
New +$2.4M 0.41% 38

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acuta Capital Partners's DNTH Position: Q1 2026 in Review

Acuta Capital Partners sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 16,708 shares — an estimated $689K sold.

Acuta Capital Partners first reported a position in DNTH in Q2 2018 and held it in 4 quarters. The position peaked at $2.29M in Q2 2018. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Acuta Capital Partners reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Acuta Capital Partners sold 16,708 Dianthus Therapeutics shares in Q1 2026, an estimated $689K.
  • Acuta Capital Partners first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 4 quarters.
  • Acuta Capital Partners's Dianthus Therapeutics position peaked at $2.29M in Q2 2018.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.